Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2010

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This is a phase I/II open label study being conducted to evaluate the overall safety and initial effectiveness of an investigational drug, Eltrombopag in patients who are 60 years of age and older and who have Acute Myelogenous Leukemia (AML). Eltrombopag is an investigational drug, which means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in this type of disease. Approximately 35 people will be enrolled on this study at the University of Pennsylvania
Epistemonikos ID: ed62524e5ad1ff2e3fea858c69be26bd344354a4
First added on: May 05, 2024